Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Integral Health Asset Management LLC

Integral Health Asset Management LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 60,000 shares of the biopharmaceutical company’s stock after buying an additional 5,000 shares during the period. Alnylam Pharmaceuticals makes up about 1.9% of Integral Health Asset Management LLC’s investment portfolio, making the stock its 11th largest position. Integral Health Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $27,360,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Geneos Wealth Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 175 shares in the last quarter. Allworth Financial LP boosted its position in Alnylam Pharmaceuticals by 11.8% during the 2nd quarter. Allworth Financial LP now owns 691 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 73 shares during the period. Vise Technologies Inc. purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $435,000. Finally, National Pension Service increased its holdings in Alnylam Pharmaceuticals by 0.8% in the 2nd quarter. National Pension Service now owns 175,046 shares of the biopharmaceutical company’s stock valued at $57,081,000 after purchasing an additional 1,387 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $313.41 on Friday. The business’s 50 day moving average is $344.35 and its two-hundred day moving average is $410.04. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The firm has a market cap of $41.56 billion, a price-to-earnings ratio of 183.28 and a beta of 0.36. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the company posted ($0.65) earnings per share. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 18th. Needham & Company LLC reduced their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Leerink Partners decreased their price target on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a report on Monday, December 15th. Raymond James Financial reaffirmed an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Finally, Royal Bank Of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $477.96.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,206 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $722,795.90. Following the transaction, the executive vice president directly owned 64,273 shares in the company, valued at $21,059,048.45. This represents a 3.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 6,799 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the transaction, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. This represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.